Boston Scientific Corporation (BSX) Shares Bought by Aperio Group LLC

Aperio Group LLC grew its stake in Boston Scientific Corporation (NYSE:BSX) by 0.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 519,407 shares of the medical equipment provider’s stock after purchasing an additional 2,830 shares during the quarter. Aperio Group LLC’s holdings in Boston Scientific were worth $12,876,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new position in shares of Boston Scientific in the third quarter valued at about $138,000. Steward Partners Investment Advisory LLC bought a new position in shares of Boston Scientific in the third quarter valued at about $139,000. Cerebellum GP LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at about $126,000. Ironwood Investment Counsel LLC bought a new position in shares of Boston Scientific in the third quarter valued at about $204,000. Finally, Perkins Capital Management Inc. bought a new position in shares of Boston Scientific in the third quarter valued at about $204,000. 90.15% of the stock is currently owned by institutional investors.

Several equities analysts have recently weighed in on the stock. Canaccord Genuity assumed coverage on shares of Boston Scientific in a research report on Tuesday, October 24th. They issued a “buy” rating and a $36.00 price objective on the stock. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Friday, October 20th. BMO Capital Markets reissued a “buy” rating and issued a $30.00 price objective on shares of Boston Scientific in a research report on Friday, October 13th. SunTrust Banks set a $34.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Barclays reissued a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Boston Scientific has an average rating of “Buy” and a consensus target price of $31.00.

Boston Scientific Corporation (BSX) opened at $26.32 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a one year low of $23.29 and a one year high of $29.93. The company has a market cap of $36,140.00, a PE ratio of 376.00, a P/E/G ratio of 1.92 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The business had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. During the same period in the prior year, the company posted $0.30 earnings per share. Boston Scientific’s revenue was up 9.9% compared to the same quarter last year. research analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.

In other news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of Boston Scientific stock in a transaction on Tuesday, November 28th. The shares were purchased at an average cost of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Michael P. Phalen sold 15,835 shares of the stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $25.25, for a total transaction of $399,833.75. The disclosure for this sale can be found here. Insiders sold 76,237 shares of company stock worth $1,996,806 over the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2018/02/08/boston-scientific-corporation-bsx-shares-bought-by-aperio-group-llc.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit